

GCC Clinical Trial Market Outlook 2025

<https://marketpublishers.com/r/G1F46C57F02BEN.html>

Date: August 2020

Pages: 330

Price: US\$ 2,400.00 (Single User License)

ID: G1F46C57F02BEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

'GCC Clinical Trial Market Outlook 2025' Report Highlights:

GCC Clinical Trial Market Opportunity: >US\$ 500 Million

GCC Disease Prevalence & Statistics

Saudi Arabia Dominating GCC Clinical Trial Landscape: > 500 Trials

Clinical Trials for Cancer in GCC: > 120 Trials

Guidelines For Conducting Clinical Trials by Country

Ongoing Clinical Trials Insight by Country

GCC clinical trial market is represented as a novel ally for the developing clinical trial market globally. In a short period of time, the market has become used to conducting some of the major research oriented clinical studies to cover large portion of diseases that have been a subject of interest for prolonged years. The overall clinical trial market landscape is providing several different advantages that is favoring the GCC region capable of conducting pharmaceutical clinical trials at a large scale. Nonetheless, the market is prone to progress at a steady state because it has an attractive regulatory framework that makes it conducive towards more clinical researches.

The growth observed in the GCC clinical trial market is filled with pool of opportunities and varying trends at the level of stakeholders and the researchers. Various obstacles

that are observed while building the clinical research capacity in the region have been well adjusted as there are several different facilitators that have optimized the high ground cost of clinical research studies. GCC clinical trial market provides an advantageous landscape of conducting clinical research as it is holding epidemiological profile and ethnic diversity. In terms of technology, concentration of the fully advanced equipments have also observed an influx in the market. All this is estimated to be a contribution of economic development that has taken place in the region so far.

The clinical research credentials such as patient enrollment, infrastructure and equipped laboratories in every country in the gulf have fundamentally revolutionized the pattern of running larger clinical trials. Saudi Arabia & UAE among all the gulf countries have helped the region to set a phenomenon that has majorly impacted several emerging clinical trial markets of the world. Clinical trial landscape in the respective countries have undergone a transitional state and have eventually resulted in alarming the other emerged markets of the world about the upcoming dominant market. Currently, both the countries are holding hundreds of clinical trials for almost half of the major mortality causing diseases in the world.

Other than the population drive that is considered as an important key parameter for the future assembly of the GCC clinical trial market, the parameter that is expected to drive the future scenario of the market is the gradual increase in the geriatric population. It is estimated that by the end of year 2050, there will be more than 25 Million people aged 60 years and above. The analysis that has been made for the future percentage of geriatric population is driving the upcoming years of the GCC clinical trial market.

The future insights of the GCC clinical trial market is estimated to bring laurels to the overall pharmaceutical market. The initiatives taken up by the government of the respective countries in long run such as Vision 2030 by Saudi Arabia is also motivating the researchers to enforce various different strategies that could boost the future of the clinical trial market as well as the pharmaceutical market.

As per the research report, the current scenario of the GCC clinical trial market represents a phase where it is moving towards disrupting the established status of other emerged markets of the world. The market is approaching several different go-to-market strategies in order to enhance the experiences as well as the insights regarding the data-driven clinical studies. With the introduction of several different smart applications in the market, it is leading towards an augmented and impactful strike against the major position holders in the global market. Over the last few years, the market is inclining towards the diseases whose prevalence in the region is increasing furiously. It is

estimated that in the near future, with the technologies to redefine the outlook, the market will hold the potential to thrive promisingly into the global market.

Contents

1. GCC CLINICAL MARKET REGIONAL INSIGHTS

2. GCC CLINICAL TRIAL MARKET DYNAMICS

2.1 Driving Forces for GCC Clinical Trial Market

2.2 Challenges for GCC Clinical Trial Market

3. GCC - REGULATORY ASPECTS OF PHARMACEUTICALS

3.1 Gulf Central Committee for Drug Registrations (GCC-DR)

3.2 Regulatory Review Process

3.3 Centralized Registration

3.4 Decentralized Drug Registration Regulation

3.4.1 Saudi Arabia

3.4.2 Kuwait

3.4.3 UAE

3.4.4 Bahrain

3.4.5 Qatar

3.4.6 Oman

3.5 Gulf Joint Procurement Program

4. GCC DISEASE PREVALENCE & STATISTICS

4.1 Cancer

4.1.1 Overview

4.1.2 Prevalence by Cancer Type & Gender

4.1.3 Cancer Prevalence & Statistics by GCC Countries

4.2 Diabetes

4.3 HIV/AIDS

4.4 Cardiovascular Diseases

4.4.1 Coronary Heart Disease

4.4.2 Hypertension

4.4.3 Stroke

4.5 Obesity

4.6 Respiratory Disorders

4.6.1 Asthma

4.6.2 Tuberculosis

- 4.6.3 Influenza & Pneumonia
- 4.6.4 Other Respiratory Diseases - COPD & Cystic Fibrosis
- 4.7 Alzheimer's Disease/Dementia

5. SAUDI ARABIA - ONGOING CLINICAL TRIALS INSIGHT

- 5.1 Overview
- 5.2 By Indication
 - 5.2.1 Cancer
 - 5.2.2 Diabetes
 - 5.2.3 Cardiovascular Diseases
 - 5.2.4 Respiratory Diseases Excluding Lung Cancer

6. SAUDI ARABIA - GUIDELINES FOR CONDUCTING CLINICAL TRIALS

- 6.1 The Principles of SFDA Guidelines
- 6.2 Protection of Trial Subjects
- 6.3 Institutional Review Board (IRB) Committee
 - 6.3.1 Responsibilities
 - 6.3.2 Composition, Functions, and Operations
 - 6.3.3 Procedures
 - 6.3.4 Records
- 6.4 Investigators
 - 6.4.1 Qualifications and Agreements
 - 6.4.2 Adequate Resources & Medical Care of Trial Subjects
- 6.5 Clinical Trial Protocols

7. UAE - ONGOING CLINICAL TRIALS INSIGHT

- 7.1 Overview
- 7.2 By Indication
 - 7.2.1 Cancer
 - 7.2.2 Diabetes
 - 7.2.3 CVS Disorders

8. UAE - GUIDELINES FOR CLINICAL TRIALS CONDUCTION

- 8.1 General Provisions For Clinical Trials
 - 8.1.1 Purpose & Scope

- 8.1.2 Clinical Trials Background
- 8.2 Suitability Of Individuals AND Sites Involved In Conducting The Clinical Trial
- 8.3 Protection of Subjects & Informed Consent
 - 8.3.1 Research Subjects
 - 8.3.2 Information and Consent
- 8.4 Clinical Trials With Vulnerable Groups (Vulnerable Subjects) Of Patients
- 8.5 Ethics & Research Committees
- 8.6 Authorization to Conduct Clinical Trials & Application to Ethics Committee
- 8.7 Amendments & Suspensions In Clinical Trials
 - 8.7.1 Amendments In Clinical Trials
 - 8.7.2 Suspension Of The Clinical Trial

9. BAHRAIN - ONGOING CLINICAL TRIALS INSIGHT

- 9.1 Overview
- 9.2 By Indication

10. BAHRAIN - GUIDELINES FOR CLINICAL TRIALS APPLICATION

- 10.1 Introduction
- 10.2 The Application Process
- 10.3 Phase II & III Clinical Trials: Decision Process
- 10.4 Guidelines Phase IV Clinical Trials
 - 10.4.1 Application Process
 - 10.4.2 DECISION PROCESS
- 10.5 Amendments

11. OMAN - ONGOING CLINICAL TRIALS INSIGHT

- 11.1 Overview
- 11.2 By Indication
 - 11.2.1 Sickle Cell Disease
 - 11.2.2 Cancer

12. OMAN - GUIDELINES FOR CLINICAL TRIAL CONDUCTION

- 12.1 Provision & Prerequisites for a Clinical Trial
- 12.2 Protection of Clinical Trial Participants
 - 12.2.1 Research and Ethics Committee

12.2.2 Informed Consent of Trial Participants

12.2.3 Privacy and Confidentiality

12.3 Documents and Requirements for Clinical Studies and Trials

12.3.1 Documents Required to be Submitted to Central RERAC for Approval of Clinical Trials

12.3.2 Documents Required During the Clinical Conduct of the Trial

12.3.3 Other Documents which are Required During the Clinical Conduct of the Trial

12.3.4 The Required Documents by the End of the Trial

13. KUWAIT - ONGOING CLINICAL TRIALS INSIGHT

13.1 Overview

13.2 By Indication

13.2.1 Cancer Related Trials

13.2.2 Diabetes Related Trial

14. QATAR - ONGOING CLINICAL TRIALS INSIGHT

14.1 Overview

14.2 By Indication

14.2.1 Cancer Related Trials

14.2.2 Diabetes Related Trial

14.2.3 CVS Disorders

14.2.4 Respiratory Disease

15. FUTURE INSIGHTS FOR GCC CLINICAL TRIAL MARKET

16. COMPETITIVE LANDSCAPE

16.1 Regional CROs

16.1.1 Innova

16.1.2 Antaea

16.1.3 ClinServ International

16.1.4 MCRO

16.1.5 KAU MED Clinical Research Organization

16.1.6 RAY CRO

16.1.7 MCT CRO

16.1.8 ClinArt MENA

16.1.9 Pharmaceutical Development Company

16.1.10 Nagy Research MEACRO

16.2 Multinational CROs

16.2.1 Quotient Sciences

16.2.2 MedPace

16.2.3 Europe, Middle East & Africa Clinical Research (EMEACR)

16.2.4 Pharmaceutical Product Development (PPD)

16.2.5 MedPace

16.2.6 PRA Health Sciences

16.2.7 KCR

16.2.8 ICON

16.2.9 Covance

16.2.10 Parexel

List Of Figures

LIST OF FIGURES

- Figure 1-1: GCC - Clinical Trials Market Opportunity (US\$ Million), 2020 -2025
- Figure 1-2: GCC – Clinical Trials for Cancer Indication, 2020
- Figure 1-3: GCC – Distribution of Clinical Trials for Different Indications
- Figure 3-1: GCC - Types of Drug Registration Process
- Figure 3-2: Process Map for GCC Centralized Registration
- Figure 3-3: GCC – Innovative/Biological and Generic Drug Registration Fees for Evaluation Procedures (SAR/US\$), 2020
- Figure 3-4: GCC – Innovative/Biological and Generic Drug Registration Renewal Fees (SAR/US\$), 2020
- Figure 3-5: GCC – Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Innovative/Biological Products (SAR/US\$), 2020
- Figure 3-6: GCC – Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Generic Products (SAR/US\$), 2020
- Figure 3-7: GCC – Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Intravenous Generic Products (SAR/US\$), 2020
- Figure 3-8: Saudi Arabia – Regulatory Process for Pharmaceuticals
- Figure 3-9: Kuwait – Regulatory Process for Pharmaceuticals
- Figure 3-10: UAE - Regulatory Process for Pharmaceuticals
- Figure 3-11: Bahrain – Regulatory Process for Pharmaceuticals
- Figure 3-12: Qatar – Regulatory Process for Pharmaceuticals
- Figure 3-13: Oman – Regulatory Process for Pharmaceuticals
- Figure 4-1: GCC – Number of Newly Diagnosed Cancer Cases & Deaths, 2018
- Figure 4-2: GCC – Number of New Cancer Cases by Countries, 2018
- Figure 4-3: GCC – New Cancer Cases by Countries (%), 2018
- Figure 4-4: GCC – Number of Cancer Related Deaths by Countries, 2018
- Figure 4-5: GCC – New Cancer Cases by Countries (%), 2018
- Figure 4-6: GCC – Number of Newly Diagnosed Cancer Cases, 2018 & 2030
- Figure 4-7: GCC – Age Standardized Cancer Incidence Rate by Countries (per 100,000 People), 2018
- Figure 4-8: GCC – Age Standardized Cancer Mortality Rate by Countries (per 100,000 People), 2018
- Figure 4-9: GCC Pharmaceutical Market Size – Total vs. Cancer Drugs (US\$ Billion), 2018
- Figure 4-10: GCC – Cancer Drug Market Size by Countries (%), 2018
- Figure 4-11: GCC – Number of New Diagnosed Cases by Cancer Type, 2018

- Figure 4-12: GCC – New Diagnosed Cases by Cancer Type (%), 2018
- Figure 4-13: GCC – Number of Cancer Cases & Deaths by Gender, 2018
- Figure 4-14: GCC – Cancer Cases by Gender (%), 2018
- Figure 4-15: GCC – Cancer Deaths by Gender (%), 2018
- Figure 4-16: GCC – Age Standardized Cancer Incidence & Mortality Rate (per 100,000 People), 2018
- Figure 4-17: Saudi Arabia – Number of Cancer Cases & Deaths, 2018
- Figure 4-18: Saudi Arabia – Number of Cancer Cases & Deaths by Gender, 2018
- Figure 4-19: Saudi Arabia – New Diagnosed Cancer Cases by Gender (%), 2018
- Figure 4-20: Saudi Arabia – Cancer Related Deaths by Gender (%), 2018
- Figure 4-21: Saudi Arabia – New Diagnosed Cases by Cancer Type (%), 2018
- Figure 4-22: UAE - Number of Cancer Cases & Deaths, 2018
- Figure 4-23: UAE – Number of Cancer Cases & Deaths by Gender, 2018
- Figure 4-24: UAE – New Diagnosed Cases by Cancer Type (%), 2018
- Figure 4-25: UAE – Number of New Diagnosed Cases by Cancer Type, 2018
- Figure 4-26: Kuwait - Number of Cancer Cases & Deaths, 2018
- Figure 4-27: Kuwait – Number of Cancer Cases & Deaths by Gender, 2018
- Figure 4-28: Kuwait – New Diagnosed Cases by Cancer Type (%), 2018
- Figure 4-29: Kuwait – Number of New Diagnosed Cases by Cancer Type, 2018
- Figure 4-30: Bahrain - Number of Cancer Cases & Deaths, 2018
- Figure 4-31: Bahrain – Number of Cancer Cases & Deaths by Gender, 2018
- Figure 4-32: Bahrain – New Diagnosed Cases by Cancer Type (%), 2018
- Figure 4-33: Bahrain – Number of New Diagnosed Cases by Cancer Type, 2018
- Figure 4-34: Qatar - Number of Cancer Cases & Deaths, 2018
- Figure 4-35: Qatar – Number of Cancer Cases & Deaths by Gender, 2018
- Figure 4-36: Qatar – New Diagnosed Cases by Cancer Type (%), 2018
- Figure 4-37: Qatar – Number of New Diagnosed Cases by Cancer Type, 2018
- Figure 4-38: Oman - Number of Cancer Cases & Deaths, 2018
- Figure 4-39: Oman – Number of Cancer Cases & Deaths by Gender, 2018
- Figure 4-40: Oman – New Diagnosed Cases by Cancer Type (%), 2018
- Figure 4-41: Oman – Number of New Diagnosed Cases by Cancer Type, 2018
- Figure 4-42: GCC – Total Adult Population & Diabetic Population (Million), 2017
- Figure 4-43: GCC – Total Adult Population & Diabetic Population (%), 2017
- Figure 4-44: GCC – Diabetic Population by Countries (Million), 2017
- Figure 4-45: GCC – Diabetic Population by Countries (%), 2017
- Figure 4-46: GCC – Diabetes Related Deaths by Countries, 2017
- Figure 4-47: GCC – Diabetes Related Deaths by Countries (%), 2017
- Figure 4-48: GCC – Diabetes Prevalence Rate by Countries (%), 2017
- Figure 4-49: GCC – Age Standardized Diabetes Death Rate by Countries (Per 100,000

People), 2017

Figure 4-50: GCC – Diabetic Population (Billion), 2017, 2018 & 2045

Figure 4-51: Saudi Arabia – Total HIV Cases & Newly Diagnosed HIV Cases, 2017

Figure 4-52: Saudi Arabia – New Diagnosed HIV Cases, 2013 - 2017

Figure 4-53: Saudi Arabia – New Diagnosed HIV Cases by Gender, 2017

Figure 4-54: Saudi Arabia - New Diagnosed HIV Cases by Gender (%), 2017

Figure 4-55: Saudi Arabia – Total HIV Cases by Gender, 2017

Figure 4-56: Saudi Arabia – Total HIV Cases by Gender, 2017

Figure 4-57: Saudi Arabia – Cumulative HIV Related Deaths by Gender, 2017

Figure 4-58: Saudi Arabia – Cumulative Number of HIV Patients on Anti-retroviral Therapy, 2017

Figure 4-59: UAE – Cumulative Number of HIV Patients, 2012, 2014 & 2016

Figure 4-60: UAE – Number of New HIV Cases & Deaths, 2016

Figure 4-61: UAE – Cumulative Number of HIV Patients on Anti-retroviral Therapy, 2012, 2014 & 2018

Figure 4-62: UAE – Cumulative Number of HIV Patients, 2014 - 2018

Figure 4-63: Bahrain – HIV Associated New Cases & Deaths, 2016

Figure 4-64: Bahrain – Patients Receiving Antiretroviral Therapy (%), 2012, 2014 & 2016

Figure 4-65: Qatar – Cumulative Number of HIV Cases & Patients on Antiretroviral Therapy, 1984 - 2014

Figure 4-66: Qatar – HIV Patients on Anti-Retroviral Therapy, 1984 - 2014

Figure 4-67: Oman – Cumulative HIV Cases, 2014, 2016 & 2018

Figure 4-68: Oman – Cumulative HIV Cases by Gender, 2018

Figure 4-69: Oman – Cumulative HIV Cases by Gender (%), 2018

Figure 4-70: Oman – Cumulative HIV Cases by Age, 2018

Figure 4-71: GCC – Age Standardized Coronary Heart Disease Death Rate by Countries, 2017

Figure 4-72: GCC – CHD Related Deaths by Countries, 2017

Figure 4-73: GCC – CHD Related Deaths by Countries (%), 2017

Figure 4-74: GCC – Age Standardized Hypertension Death Rate by Countries, 2017

Figure 4-75: GCC – Hypertension Related Deaths by Countries, 2017

Figure 4-76: GCC – Hypertension Related Deaths by Countries (%), 2017

Figure 4-77: GCC – Age Standardized Stroke Death Rate by Countries, 2017

Figure 4-78: GCC – Stroke Related Deaths by Countries, 2017

Figure 4-79: GCC – Stroke Related Deaths by Countries (%), 2017

Figure 4-80: GCC – Obese Population by Countries (%), 2019

Figure 4-81: GCC – Body Mass Index by Countries, 2019

Figure 4-82: Saudi Arabia – Obesity Prevalence Rate (%), 2017 & 2022

- Figure 4-83: Saudi Arabia – Obesity Prevalence Rate by Gender (%), 2017 & 2022
- Figure 4-84: UAE – Prevalence Rate of Obesity & Overweight by Gender(%), 2016
- Figure 4-85: UAE – Obese Adult Population (%), 2019
- Figure 4-86: Kuwait – Prevalence Rate of Obesity & Overweight (%), 2016
- Figure 4-87: Kuwait – Prevalence Rate of Obesity & Overweight by Gender (%), 2016
- Figure 4-88: Bahrain – Prevalence Rate of Obesity & Overweight (%), 2016
- Figure 4-89: Bahrain – Prevalence Rate of Obesity & Overweight by Gender (%), 2016
- Figure 4-90: Qatar – Prevalence Rate of Obesity & Overweight (%), 2016
- Figure 4-91: Qatar – Prevalence Rate of Obesity & Overweight by Gender (%), 2016
- Figure 4-92: Oman – Obesity Prevalence Rate by Gender (%), 2016
- Figure 4-93: GCC – Asthma Related Deaths by Countries, 2017
- Figure 4-94: GCC – Asthma Related Deaths by Countries (%), 2017
- Figure 4-95: GCC – Age Standardized Asthma Death Rate by Countries (per 100,000 People), 2017
- Figure 4-96: GCC – Tuberculosis Related Deaths by Countries, 2017
- Figure 4-97: GCC – Age Standardized Incidence Rate of Tuberculosis by Countries (Per 100,000 People), 2017
- Figure 4-98: GCC – Asthma Related Deaths by Countries (%), 2017
- Figure 4-99: GCC – Age Standardized Tuberculosis Death Rate by Countries (per 100,000 People), 2017
- Figure 4-100: GCC – Influenza & Pneumonia Related Deaths by Countries, 2017
- Figure 4-101: GCC – Influenza & Pneumonia Related Deaths by Countries (%), 2017
- Figure 4-102: GCC – Age Standardized Influenza & Pneumonia Death Rate by Countries (per 100,000 People), 2017
- Figure 4-103: GCC – COPD Prevalence Rate by Countries (%), 2018
- Figure 4-104: GCC – COPD & Cystic Fibrosis Related Deaths by Countries, 2017
- Figure 4-105: GCC – COPD & Cystic Fibrosis Related Deaths by Countries (%), 2017
- Figure 4-106: GCC – Age Standardized COPD & Cystic Fibrosis Death Rate by Countries (per 100,000 People), 2017
- Figure 4-107: GCC – Alzheimer/Dementia Related Deaths by Countries, 2017
- Figure 4-108: GCC – Alzheimer/Dementia Related Deaths by Countries (%), 2017
- Figure 4-109: GCC – Age Standardized Alzheimer/Dementia Death Rate by Countries (per 100,000 People), 2017
- Figure 5-1: Saudi Arabia – Number of Clinical Trials by Development Phase, 2020
- Figure 5-2: Saudi Arabia – Clinical Trials by Development Phase (%), 2020
- Figure 5-3: Saudi Arabia – Number of Clinical Trials by Status, 2020
- Figure 5-4: Saudi Arabia – Number of Drugs in Clinical Trials by Development Phase, 2020
- Figure 5-5: Saudi Arabia – Drugs in Clinical Trials by Development Phase (%), 2020

Figure 5-6: Saudi Arabia – Number of Drugs in Clinical Trials by Top 20 Indication, 2020

Figure 5-7: Saudi Arabia – Number of Drugs in Clinical Trials by Top 15 Drug Class, 2020

Figure 5-8: Saudi Arabia – Number of Drugs in Clinical Trials by Mechanism of Action, 2020

Figure 5-9: Saudi Arabia – Numbers of Clinical Trials by Indications, 2020

Figure 5-10: Saudi Arabia – Clinical Trials by Indications (%), 2020

Figure 5-11: Saudi Arabia – Number of Cancer Clinical Trials by Development Phase, 2020

Figure 5-12: Saudi Arabia – Cancer Clinical Trials by Development Phase (%), 2020

Figure 5-13: Saudi Arabia – Number of Cancer Clinical Trials by Status, 2020

Figure 5-14: Saudi Arabia – Cancer Clinical Trials by Status (%), 2020

Figure 5-15: Saudi Arabia – Number of Clinical Trials by Cancer Type, 2020

Figure 5-16: Saudi Arabia – Clinical Trials by Cancer Type (%), 2020

Figure 5-17: Saudi Arabia – Number of Breast Cancer Clinical Trials by Development Phase, 2020

Figure 5-18: Saudi Arabia – Breast Cancer Clinical Trials by Development Phase (%), 2020

Figure 5-19: Saudi Arabia – Number of Breast Cancer Clinical Trials by Status, 2020

Figure 5-20: Saudi Arabia – Number of Lung Cancer Clinical Trials by Development Phase, 2020

Figure 5-21: Saudi Arabia – Lung Cancer Clinical Trials by Development Phase (%), 2020

Figure 5-22: Saudi Arabia – Number of Lung Cancer Clinical Trials by Status, 2020

Figure 5-23: Saudi Arabia – Number of Leukemia Clinical Trials by Development Phase, 2020

Figure 5-24: Saudi Arabia – Leukemia Clinical Trials by Development Phase (%), 2020

Figure 5-25: Saudi Arabia – Number of Leukemia Clinical Trials by Status, 2020

Figure 5-26: Saudi Arabia – Number of Lymphoma Clinical Trials by Development Phase, 2020

Figure 5-27: Saudi Arabia – Lymphoma Clinical Trials by Development Phase (%), 2020

Figure 5-28: Saudi Arabia – Number of Lymphoma Clinical Trials by Status, 2020

Figure 5-29: Saudi Arabia – Total Clinical Trials v/s Diabetes Clinical Trial 2020

Figure 5-30: Saudi Arabia – Diabetes Clinical Trial by Type, 2020

Figure 5-31: Saudi Arabia – Diabetes Clinical Trial by Type, 2020

Figure 5-32: Saudi Arabia – Number of Diabetes Related Clinical Trials by Development Phase, 2020

Figure 5-33: Saudi Arabia – Number of Diabetes Related Clinical Trials by Development Phase, 2020

- Figure 5-34: Saudi Arabia – Number of Clinical Trials by Status, 2020
- Figure 5-35: Saudi Arabia – Total Clinical Trials v/s CVS Related Clinical Trial 2020
- Figure 5-36: Saudi Arabia – CVS Clinical Trial by Type of Disease, 2020
- Figure 5-37: Saudi Arabia – CVS Clinical Trial by Disease Type (%), 2020
- Figure 5-38: Saudi Arabia – Number of CVS Related Clinical Trials by Development Phase, 2020
- Figure 5-39: Saudi Arabia – Number of CVS Related Clinical Trials by Development Phase, 2020
- Figure 5-40: Saudi Arabia – Number of CVS Related Clinical Trials by Status, 2020
- Figure 5-41: Saudi Arabia – Total Clinical Trials v/s Respiratory Diseases (Excluding Lung Cancer) Clinical Trials, 2020
- Figure 5-42: Saudi Arabia – Number of Respiratory Diseases (Excluding Lung Cancer) Related Clinical Trials by Development Phase, 2020
- Figure 5-43: Saudi Arabia – Number of Respiratory Diseases (Excluding Lung Cancer) Related Clinical Trials by Development Phase, 2020
- Figure 5-44: Saudi Arabia – Number of Respiratory Diseases (Excluding Lung Cancer) Related Clinical Trials by Status, 2020
- Figure 7-1: UAE – Number of Clinical Trials by Development Phase, 2020
- Figure 7-2: UAE – Clinical Trials by Development Phase (%), 2020
- Figure 7-3: UAE – Number of Clinical Trials by Status, 2020
- Figure 7-4: UAE – Number of Drugs in Clinical Trials by Development Phase, 2020
- Figure 7-5: UAE – Drugs in Clinical Trials by Development Phase (%), 2020
- Figure 7-6: UAE – Number of Drugs in Clinical Trials by Top 20 Indication, 2020
- Figure 7-7: UAE – Number of Drugs in Clinical Trials by Top 15 Drug Class, 2020
- Figure 7-8: UAE – Number of Drugs in Clinical Trials by Mechanism of Action, 2020
- Figure 7-9: UAE – Numbers of Clinical Trials by Indications, 2020
- Figure 7-10: UAE – Clinical Trials by Indications (%), 2020
- Figure 7-11: UAE – Number of Cancer Clinical Trials by Development Phase, 2020
- Figure 7-12: UAE – Cancer Clinical Trials by Development Phase (%), 2020
- Figure 7-13: UAE – Number of Cancer Clinical Trials by Status, 2020
- Figure 7-14: UAE – Cancer Clinical Trials by Status (%), 2020
- Figure 7-15: UAE – Number of Clinical Trials by Cancer Type, 2020
- Figure 7-16: UAE – Clinical Trials by Cancer Type (%), 2020
- Figure 7-17: UAE – Number of Breast Cancer Clinical Trials by Development Phase, 2020
- Figure 7-18: UAE – Breast Cancer Clinical Trials by Developmental Stage (%), 2020
- Figure 7-19: UAE – Number of Breast Cancer Clinical Trials by Status, 2020
- Figure 7-20: UAE – Number of Breast Cancer Clinical Trials by Development Phase, 2020

Figure 7-21: UAE – Breast Cancer Clinical Trials by Developmental Stage (%), 2020

Figure 7-22: UAE – Number of Breast Cancer Clinical Trials by Status, 2020

Figure 7-23: UAE – Total Clinical Trials v/s Diabetes Clinical Trial 2020

Figure 7-24: UAE – Diabetes Clinical Trial by Type, 2020

Figure 7-25: UAE – Diabetes Clinical Trial by Type, 2020

Figure 7-26: UAE – Number of Diabetes Related Clinical Trials by Development Phase, 2020

Figure 7-27: UAE – Number of Diabetes Related Clinical Trials by Development Phase, 2020

Figure 7-28: UAE – Number of Clinical Trials by Status, 2020

Figure 7-29: UAE – Total Clinical Trials v/s CVS Related Clinical Trial 2020

Figure 7-30: UAE – CVS Clinical Trial by Type of Disease, 2020

Figure 7-31: UAE – CVS Clinical Trial by Disease Type (%), 2020

Figure 7-32: UAE – Number of CVS Related Clinical Trials by Development Phase, 2020

Figure 7-33: UAE – Number of CVS Related Clinical Trials by Development Phase, 2020

Figure 7-34: UAE – Number of CVS Related Clinical Trials by Status, 2020

Figure 9-1: Bahrain – Number of Clinical Trials by Development Phase, 2020

Figure 9-2: Bahrain – Clinical Trials by Development Phase (%), 2020

Figure 9-3: Bahrain – Number of Clinical Trials by Status, 2020

Figure 9-4: Bahrain – Number of Drugs in Clinical Trials by Development Phase, 2020

Figure 9-5: Bahrain – Drugs in Clinical Trials by Development Phase (%), 2020

Figure 9-6: Bahrain – Number of Drugs in Clinical Trials by Top 20 Indication, 2020

Figure 9-7: Bahrain – Number of Drugs in Clinical Trials by Top 15 Drug Class, 2020

Figure 9-8: Bahrain – Number of Drugs in Clinical Trials by Mechanism of Action, 2020

Figure 9-9: Bahrain – Numbers of Clinical Trials by Indications, 2020

Figure 9-10: Bahrain – Clinical Trials by Indications (%), 2020

Figure 9-11: Bahrain – Number of COVID 19 Clinical Trials by Development Phase, 2020

Figure 9-12: Bahrain – COVID 19 Clinical Trials by Development Phase (%), 2020

Figure 9-13: Bahrain – Number of Clinical Trials by Status, 2020

Figure 11-1: Oman – Number of Clinical Trials by Development Phase, 2020

Figure 11-2: Oman – Clinical Trials by Development Phase (%), 2020

Figure 11-3: Oman – Number of Clinical Trials by Status, 2020

Figure 11-4: Oman – Number of Drugs in Clinical Trials by Development Phase, 2020

Figure 11-5: Oman – Drugs in Clinical Trials by Development Phase (%), 2020

Figure 11-6: Oman – Number of Drugs in Clinical Trials by Top 20 Indication, 2020

Figure 11-7: Oman – Number of Drugs in Clinical Trials by Top 15 Drug Class, 2020

Figure 11-8: Oman – Number of Drugs in Clinical Trials by Mechanism of Action, 2020

Figure 11-9: Oman – Numbers of Clinical Trials by Indications, 2020

Figure 11-10: Oman – Clinical Trials by Indications (%), 2020

Figure 11-11: Oman – Number of Sickle Cell Disease Clinical Trials by Development Phase, 2020

Figure 11-12: Oman – Sickle Cell Disease Clinical Trials by Development Phase (%), 2020

Figure 11-13: Oman – Number of Sickle Cell Disease Clinical Trials by Status, 2020

Figure 11-14: Oman – Number of Cancer Clinical Trials by Status, 2020

Figure 11-15: Oman – Cancer Clinical Trials by Status (%), 2020

Figure 11-16: Oman – Number of Clinical Trials by Type of Cancer, 2020

Figure 11-17: Oman – Clinical Trials by Type of Cancer (%), 2020

Figure 13-1: Kuwait – Number of Clinical Trials by Development Phase, 2020

Figure 13-2: Kuwait – Clinical Trials by Development Phase (%), 2020

Figure 13-3: Kuwait – Number of Clinical Trials by Status, 2020

Figure 13-4: Kuwait – Number of Drugs in Clinical Trials by Development Phase, 2020

Figure 13-5: Kuwait – Drugs in Clinical Trials by Development Phase (%), 2020

Figure 13-6: Kuwait – Number of Drugs in Clinical Trials by Top 20 Indication, 2020

Figure 13-7: Kuwait – Number of Drugs in Clinical Trials by Top 15 Drug Class, 2020

Figure 13-8: Kuwait – Number of Drugs in Clinical Trials by Mechanism of Action, 2020

Figure 13-9: Kuwait – Numbers of Clinical Trials by Indications, 2020

Figure 13-10: Kuwait – Clinical Trials by Indications (%), 2020

Figure 13-11: Kuwait – Number of Cancer Clinical Trials by Development Phase, 2020

Figure 13-12: Kuwait – Cancer Clinical Trials by Development Phase (%), 2020

Figure 13-13: Kuwait – Number of Cancer Clinical Trials by Status, 2020

Figure 13-14: Kuwait – Number of Clinical Trials by Type of Cancer, 2020

Figure 13-15: Kuwait – Total Clinical Trials v/s Diabetes Clinical Trial 2020

Figure 13-16: Kuwait – Diabetes Clinical Trial by Type, 2020

Figure 13-17: Kuwait – Diabetes Clinical Trial by Type, 2020

Figure 13-18: Kuwait – Number of Diabetes Related Clinical Trials by Development Phase, 2020

Figure 13-19: Kuwait – Number of Diabetes Related Clinical Trials by Development Phase, 2020

Figure 13-20: Kuwait – Number of Clinical Trials by Status, 2020

Figure 14-1: Qatar – Number of Clinical Trials by Development Phase, 2020

Figure 14-2: Qatar – Clinical Trials by Development Phase (%), 2020

Figure 14-3: Qatar – Number of Clinical Trials by Status, 2020

Figure 14-4: Qatar – Number of Drugs in Clinical Trials by Development Phase, 2020

Figure 14-5: Qatar – Drugs in Clinical Trials by Development Phase (%), 2020

Figure 14-6: Qatar – Number of Drugs in Clinical Trials by Top 20 Indication, 2020

Figure 14-7: Qatar – Number of Drugs in Clinical Trials by Top 15 Drug Class, 2020

Figure 14-8: Qatar – Number of Drugs in Clinical Trials by Top Mechanism of Action, 2020

Figure 14-9: Qatar – Numbers of Clinical Trials by Indications, 2020

Figure 14-10: Qatar – Clinical Trials by Indications (%), 2020

Figure 14-11: Qatar – Number of Cancer Clinical Trials by Development Phase, 2020

Figure 14-12: Qatar – Cancer Clinical Trials by Development Phase (%), 2020

Figure 14-13: Qatar – Number of Cancer Clinical Trials by Status, 2020

Figure 14-14: Qatar – Number of Clinical Trials by Type of Cancer, 2020

Figure 14-15: Qatar – Total Clinical Trials v/s Diabetes Clinical Trial 2020

Figure 14-16: Qatar – Diabetes Clinical Trial by Type, 2020

Figure 14-17: Qatar – Diabetes Clinical Trial by Type, 2020

Figure 14-18: Qatar – Number of Diabetes Related Clinical Trials by Development Phase, 2020

Figure 14-19: Qatar – Number of Diabetes Related Clinical Trials by Development Phase, 2020

Figure 14-20: Qatar – Number of Clinical Trials by Status, 2020

Figure 14-21: Qatar – Total Clinical Trials v/s CVS Related Clinical Trial 2020

Figure 14-22: Qatar – CVS Clinical Trial by Type of Disease, 2020

Figure 14-23: Qatar – Number of CVS Related Clinical Trials by Development Phase, 2020

Figure 14-24: Qatar – Number of CVS Related Clinical Trials by Development Phase, 2020

Figure 14-25: Qatar – Number of CVS Related Clinical Trials by Status, 2020

Figure 14-26: Qatar – Total Clinical Trials v/s Respiratory Disease (Except Lung Cancer) Related Clinical Trial 2020

Figure 14-27: Qatar – Number of Respiratory Diseases (Excluding Lung Cancer) Related Clinical Trials by Development Phase, 2020

Figure 14-28: Qatar – Number of Respiratory Diseases (Excluding Lung Cancer) Related Clinical Trials by Development Phase, 2020

Figure 14-29: Qatar – Number of Respiratory Diseases (Excluding Lung Cancer) Related Clinical Trials by Status, 2020

I would like to order

Product name: GCC Clinical Trial Market Outlook 2025

Product link: <https://marketpublishers.com/r/G1F46C57F02BEN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1F46C57F02BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970